Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis. In this one-year, 10-subject dose escalation clinical trial, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy achieved a 90% reduction (p = 0.0039) in annualized relapse rate (ARR) in subjects who received one of the three dosage levels; the doses were 6 - 9 x 10(6), 30 - 45 x 10(6) or 60 - 90 x 10(6) attenuated T-cells. Subjects in the study received subcutaneous injections of Tovaxin over a period of 20 weeks (0, 4, 12 and 20 weeks) and were monitored for an additional 32 weeks.

The safety profile for all dosage levels revealed no severe adverse reactions related to T-cell vaccination. With increasing dosage, an increase in mild injection site reactions was observed and these resolved within 48 hours.

All subjects currently are enrolled in an extension study to collect longitudinal safety and effectiveness data.

David McWilliams, president and chief executive officer of Opexa, commented, "We are particularly encouraged by the data from this dose escalation trial. While all three dosage levels were safe and effective, the group treated with the 30 - 45 x 10(6) T-cell dose achieved a 100% reduction in ARR. The currently enrolling Tovaxin IIb clinical trial is being conducted with the 30 - 45 x 10(6) T-cell dose."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T- cell vaccination with clinically isolated syndrome (CIS
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... , HAMBURG , Feb. 3 ... Wound Therapy (NPWT) will assemble this week to develop a ... NPWT Expert Panel is drafting recommendations for a range of ... published clinical evidence.  Where published evidence is insufficient, the Panel ...
... Feb. 2 Celsis In Vitro, Inc. (Celsis IVT) ... XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. ... Illinois in Chicago .  XenoTech and Sekisui Medical ... processes and methods performed by XenoTech associated with its in ...
Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
(Date:9/2/2014)... 2014 4 pm EDT): In a Viewpoint published today ... , a team of Boston researchers call for the ... in the United States. The researchers from the Friedman ... Harvard University and Boston Children,s Hospital write that policies ... could both help people make meaningful dietary changes and ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud to ... contemporary marketing presence and visually solidifies the relationship ... Senior Options,” said Stephen A. Yenchek, president and ... logo, we are making sure that our identity ... families.” , Friendship Village is a retirement community ...
(Date:9/2/2014)... Los Angeles, CA (PRWEB) September 02, 2014 ... an article on its website titled “Why You Should ... more than 80 percent of the global population breathes ... droplets and particles of pollution lodge in the skin’s ... the body’s natural barrier to free radicals that may ...
(Date:9/2/2014)... 2014 In a large population-based study of ... mild cognitive impairment (MCI) occurred twice more often ... Interestingly, this strong association was only observed in ... (66-80 years) the association vanished. This study is ... . , The concept of MCI describes an ...
(Date:9/2/2014)... 02, 2014 The Dream2Walk Foundation along with ... Sept. 14th, 2014 during Spinal Cord Injury Awareness Month featuring ... England, and Chuck Ligon. Linear Automotive will be there hosting ... , Doors open at 2pm. The car show is Pre ... free pass to the concert. There will be trophies for ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... Releases First-year Results of Guiding Stars, ... Rating System, SCARBOROUGH, Maine, Sept. 6 Consumer,selection ... are outpacing,selection of those that don,t in many aisles ... times faster -- according to data in the year,since ...
... a proven treatment -, BELLEVILLE, ON, Sept. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... in order to be able to respond to ... equine influenza outbreak.,The outbreak began in August, and ...
... MYL ) today announced that Mylan Pharmaceuticals Inc. has ... for its,Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, ... Carvedilol Tablets are the generic version of GlaxoSmithKline,s,Coreg(R) Tablets. ... the 12 months ending June 30, 2007, for the ...
... Mich. More than 10 percent of women with ... of joint and muscle pain, according to a new ... Cancer Center. , The women in the study were ... block the production of estrogen, which fuels some breast ...
... a national,ground beef producer, is voluntarily recalling from ... ground beef patties, sold fresh,under the Shaw,s label, ... on Wednesday September 5, 2007 approximately between 7am ... product has been removed from saledue,to concerns about ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") said ... dividend of $0.475 per share, payable in cash,on September ... 2007. The,dividend is the third quarterly installment of the ... is a leading healthcare real estate investment trust. Its,diverse ...
Cached Medicine News:Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 2Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4
Forceps, delicate, straight....
Jewelers Forceps, standard, straight....
1 mm x 6 mm oval hole....
Jewelers forceps. Insulated....
Medicine Products: